MX2018007426A - Metodos de uso de interleucina 10 para el tratamiento de enfermedades y transtornos. - Google Patents
Metodos de uso de interleucina 10 para el tratamiento de enfermedades y transtornos.Info
- Publication number
- MX2018007426A MX2018007426A MX2018007426A MX2018007426A MX2018007426A MX 2018007426 A MX2018007426 A MX 2018007426A MX 2018007426 A MX2018007426 A MX 2018007426A MX 2018007426 A MX2018007426 A MX 2018007426A MX 2018007426 A MX2018007426 A MX 2018007426A
- Authority
- MX
- Mexico
- Prior art keywords
- methods
- interleukin
- disorders
- treating diseases
- disorder
- Prior art date
Links
- 102000003814 Interleukin-10 Human genes 0.000 title 1
- 108090000174 Interleukin-10 Proteins 0.000 title 1
- 208000037765 diseases and disorders Diseases 0.000 title 1
- 229940076144 interleukin-10 Drugs 0.000 title 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 4
- 201000010099 disease Diseases 0.000 abstract 2
- 208000035475 disorder Diseases 0.000 abstract 2
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/20—Interleukins [IL]
- A61K38/2066—IL-10
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/20—Interleukins [IL]
- A61K38/208—IL-12
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
- A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/54—Interleukins [IL]
- C07K14/5428—IL-10
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/54—Interleukins [IL]
- C07K14/5434—IL-12
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/10—Fusion polypeptide containing a localisation/targetting motif containing a tag for extracellular membrane crossing, e.g. TAT or VP22
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Toxicology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Dermatology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662275127P | 2016-01-05 | 2016-01-05 | |
| PCT/US2016/068945 WO2017120081A1 (en) | 2016-01-05 | 2016-12-28 | Methods of using interleukin-10 for treating diseases and disorders |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2018007426A true MX2018007426A (es) | 2018-11-09 |
Family
ID=59274328
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2018007426A MX2018007426A (es) | 2016-01-05 | 2016-12-28 | Metodos de uso de interleucina 10 para el tratamiento de enfermedades y transtornos. |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US20180369337A1 (enExample) |
| EP (1) | EP3400067A4 (enExample) |
| JP (1) | JP2019505493A (enExample) |
| KR (1) | KR20180100133A (enExample) |
| CN (1) | CN108430583A (enExample) |
| AU (1) | AU2016385474A1 (enExample) |
| CA (1) | CA3008284A1 (enExample) |
| MX (1) | MX2018007426A (enExample) |
| WO (1) | WO2017120081A1 (enExample) |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2367891T3 (es) * | 2000-09-29 | 2011-11-10 | Schering Corporation | Interleucina-10 pegilada. |
| US20040009146A1 (en) * | 2002-02-26 | 2004-01-15 | Osvaldo Podhajcer | Anti-tumor vaccine and method |
| CA2664304C (en) * | 2006-09-28 | 2017-08-22 | Schering Corporation | Use of pegylated il-10 to treat cancer |
| HK1215681A1 (zh) * | 2013-04-18 | 2016-09-09 | Armo Biosciences, Inc. | 使用白细胞介素-10治疗疾病和病症的方法 |
-
2016
- 2016-12-28 CN CN201680077588.8A patent/CN108430583A/zh active Pending
- 2016-12-28 CA CA3008284A patent/CA3008284A1/en not_active Abandoned
- 2016-12-28 MX MX2018007426A patent/MX2018007426A/es unknown
- 2016-12-28 JP JP2018531186A patent/JP2019505493A/ja not_active Withdrawn
- 2016-12-28 WO PCT/US2016/068945 patent/WO2017120081A1/en not_active Ceased
- 2016-12-28 EP EP16884214.4A patent/EP3400067A4/en not_active Withdrawn
- 2016-12-28 KR KR1020187019681A patent/KR20180100133A/ko not_active Withdrawn
- 2016-12-28 US US16/061,583 patent/US20180369337A1/en not_active Abandoned
- 2016-12-28 AU AU2016385474A patent/AU2016385474A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| JP2019505493A (ja) | 2019-02-28 |
| KR20180100133A (ko) | 2018-09-07 |
| CA3008284A1 (en) | 2017-07-13 |
| EP3400067A1 (en) | 2018-11-14 |
| AU2016385474A1 (en) | 2018-07-05 |
| WO2017120081A1 (en) | 2017-07-13 |
| CN108430583A (zh) | 2018-08-21 |
| US20180369337A1 (en) | 2018-12-27 |
| EP3400067A4 (en) | 2019-08-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2018002723A (es) | Macrociclicos peptidomimeticos y usos de los mismos. | |
| PH12019501575A1 (en) | ISOFORM-SPECIFIC, CONTEXT-PERMISSIVE TGFá1 INHIBITORS AND USE THEREOF | |
| PH12016500840A1 (en) | Methods of using interleukin-10 for treating diseases and disorders | |
| HK1246201A1 (zh) | 用於治疗癌症的聚乙二醇化白细胞介素-10 | |
| PH12021550542A1 (en) | Multivalent pneumococcal vaccines | |
| MX2017015574A (es) | Inhibidores de tirosina quinasa de bruton. | |
| PH12016501809A1 (en) | Heterocyclic compounds for use in the treatment of pi3k-gamma mediated disorders | |
| PH12018500586B1 (en) | Farnesoid x receptor agonists and uses thereof | |
| MY199027A (en) | Method for treating or preventing ophthalmological conditions | |
| EP3662903A3 (en) | Combination therapies | |
| WO2016004305A3 (en) | Inhibitors of bruton's tyrosine kinase | |
| BR112017002637A2 (pt) | métodos para tratar ou prevenir condições oftalmológicas | |
| MX2019005401A (es) | Metodos para tratar el sindrome de alport con bardoxolona metilo o analogos de la misma. | |
| MX379318B (es) | Metodos para tratar trastornos de sueño de ritmo circadiano. | |
| BR112017018964A2 (pt) | uso de plinabulin e métodos para tratar tumor cerebral | |
| PH12018500887A1 (en) | Anti-htra1 antibodies and methods of use thereof | |
| MX2017000141A (es) | Nanoparticulas terapeuticas dirigidas y metodos para elaborar y utilizar las mismas. | |
| WO2015031598A3 (en) | Therapeutic dnp derivatives and methods using same | |
| EP4606387A3 (en) | Methods of using interleukin-10 for treating diseases and disorders | |
| PH12021550121A1 (en) | Methods of treating hfpef employing dapagliflozin and compositions comprising the same | |
| HK1219896A1 (zh) | 使用4-氨基-2-(2，6-二氧代-呱啶-3-基)-异吲哚啉-1，3-二酮治疗和控制中枢神经系统癌症的方法和组合物 | |
| PH12018502318A1 (en) | Compositions and methods for treatment of inflammation of infection of the eye | |
| HK1245671A1 (zh) | 使用白细胞介素-10治疗疾病和病症的方法 | |
| MX2019003314A (es) | Metodos de tratamiento de la elevacion de dominio 3 de inmunoglobulina de celula t y mucina (tim-3). | |
| MX2018007408A (es) | Uso de adyuvantes para la prevencion y/o el tratamiento de enfermedades autoinmunes. |